Dr. Michael A. Gold, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 472
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
OK license 19758
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Saint Francis Hospital, Inc Tulsa, OK
- Ascension St John Medical Center Tulsa, OK
- Hillcrest Medical Center Tulsa, OK
- Saint Francis Hospital Muskogee Muskogee, OK
- Oklahoma State University Medical Center Tulsa, OK
Medical groups
- Board of Regents of the University of Oklahoma Ou Physicians Tulsa (81 clinicians)
- Oklahoma Cancer Specialists and Research Institute, LLC (47 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 472
- Services billed
- 109,769
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, nivolumab, 1 mg | 14,860 | 12 |
| Injection, ferric carboxymaltose, 1 mg | 11,250 | 14 |
| Injection, oxaliplatin, 0.5 mg | 9,000 | 15 |
| Injection, paclitaxel, 1 mg | 6,736 | 20 |
| Injection, granisetron, extended-release, 0.1 mg | 5,900 | 36 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5,025 | 57 |
| Injection, aprepitant, 1 mg | 4,810 | 21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,441 | 99 |
| Injection, denosumab, 1 mg | 1,620 | 13 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 940 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 8 payments worth $5,399 in total to this clinician.
| GlaxoSmithKline, LLC. | $2,800 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $2,496 |
| Merck Sharp & Dohme LLC | $25.70 |
| Incyte Corporation | $21.47 |
| Janssen Biotech, Inc. | $20.94 |
| Novartis Pharmaceuticals Corporation | $18.91 |
| Astellas Pharma US Inc | $15.92 |
| Consulting Fee | $5,260 |
|---|---|
| Food and Beverage | $114 |
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Jul 9, 2025 | Consulting Fee | $2,800 |
| AstraZeneca Pharmaceuticals LP Jan 9, 2025 | Consulting Fee | $2,460 |
| Merck Sharp & Dohme LLC Mar 31, 2025 | Education KEYTRUDA · ONCOLOGY · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $177,117 in research payments for these studies, mostly to the institutions running them.
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Merck Sharp & Dohme LLC - A phase 3, randomized, double-blind, multicenter study of dostarlimab
GlaxoSmithKline, LLC. - Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie Inc. · Active, not recruiting · NCT05445778 - A phase 3, randomized, double-blind, placebo-controlled, multicenter s
GlaxoSmithKline, LLC. - A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Daiichi Sankyo Inc. · Active, not recruiting · NCT04707248 - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Ca…
Merck Sharp & Dohme LLC - A prospective lowinterventional phase 4 single arm study of ocular assessments in patients treated with tivdak in recurrent or metastatic cervical cancer
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.